Evaluation of the diagnostic value of YiDiXie™-SS and YiDiXie™-HS in endometrial carcinoma

Yutong Wu[1,2,3#], Yan Li[4#], Chen Sun[1,2,5#], Zhenjian Ge[1,2,3], Wenkang Chen[1,2,3], Yingqi Li[1,2,6], Shengjie Lin[1,2,3], Pengwu Zhang[1,2], Wuping Wang[1,2,6], Siwei Chen[1,2,6], Huimei Zhou[1,2,5], Xutai Li[1,2,5], Wei Li[7], Huiying Hu[8*], Yanni Han[9*], Yongqing Lai[1,2*]

1 Department of Urology, Peking University Shenzhen Hospital, Shenzhen, 518036; 2Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036; 3 Shantou University Medical College, Shantou, Guangdong 515041; 4 Wuzhong Maternal and Child Health Hospital, Wuzhong, Ningxia 751199; 5 The Fifth Clinical Medical College of Anhui Medical University, Hefei 230032; 6 Shenzhen University Health Science Center, Shenzhen, China 518055; 7 Shenzhen KeRuiDa Health Technology Co. , Ltd. , Shenzhen, 518071; 8 Department of Ultrasound, Peking University Shenzhen Hospital, Shenzhen, 518036; 9 Department of Specialized Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036.

# Contributed equally to this work.

*Corresponding author: Yongqing Lai, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: yqlord@163. com. Yanni Han, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: 2522649101@qq.com. Huiying Hu, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: 2423301581@qq.com.

Background: Endometrial cancer represents a significant challenge to human health and is associated with a considerable economic burden. Ultrasound is a commonly employed modality in the screening and preliminary diagnosis of endometrial cancer. However, false-positive ultrasound results can lead to misdiagnosis, patients have to bear unnecessary distress, expensive examination costs, examination injuries and other adverse consequences; while false-negative ultrasound results will result in delayed treatment, and patients will thus have to bear the adverse consequences of a poor prognosis, high treatment costs, poor quality of life and short survival. It is imperative to identify convenient, cost-effective and non-invasive diagnostic techniques to minimize the prevalence of false positives and false negatives in uterine ultrasound. The objective of this study was to assess the diagnostic efficacy of YiDiXie™-SS and YiDiXie™-HS in the context of endometrial cancer.

Patients and methods: The final number of study subjects included in this study was 74, comprising 58 cases of malignant disease and 16 cases of benign disease. The remaining serum samples from the subjects were collected and tested using the YiDiXie™ all-cancer detection kit, with the objective of evaluating the sensitivity and specificity of the YiDiXie™-SS and YiDiXie™-HS, respectively.

Results: The sensitivity of YiDiXie™-SS was 98.3% (95% CI: 90.9% - 99.9%) and its specificity was 62.5% (95% CI: 38.6% - 81.5%). YiDiXie™-HS had a sensitivity of 82.8% (95% CI: 71.1% - 90.4%) and its specificity was 81.3% (95% CI: 57.0% - 93.4%). The sensitivity of YiDiXie™-SS in patients with a positive uterine ultrasound was 95.0% (95% CI: 76.4% - 99.7%), while the specificity was 75.0% (95% CI: 30.1% - 98.7%). This indicates that the utilisation of YiDiXie™-SS has the potential to reduce the incidence of false-positive uterine ultrasound results by 75.0% (95% CI: 30.1% - 98.7%), while simultaneously minimising the likelihood of malignancy leakage. The YiDiXie™-HS in patients with a negative uterine ultrasound was 81.6% (95% CI: 66.6% - 90.8%), while the specificity was 83.3% (95% CI: 55.2% - 97.0%). This suggests a reduction of 81.6% (95% CI: 66.6% - 90.8%) in the rate of false-negative uterine ultrasound with the application of YiDiXie™-HS.

Conclusion: YiDiXie™-SS is an effective method for reducing the rate of uterine ultrasound false positives while maintaining a low incidence of delayed treatment of malignancies. YiDiXie™-HS has been demonstrated to significantly reduce the rate of false-negative uterine ultrasound results. YiDiXie™-SS and YiDiXie™-HS have significant diagnostic value in endometrial cancer, and are expected to solve the two problems of 'high false positive rate of uterine ultrasound' and 'high false negative rate of uterine ultrasound' in endometrial tumors.

Clinical trial number: ChiCTR2200066840.

Key words: Endometrial carcinoma, Uterine ultrasound, False-positive, False-negative, YiDiXie™-SS, YiDiXie™-HS

INTRODUCTION

Endometrial cancer (EC) is one of the most prevalent malignant neoplasms in the field of obstetrics and gynaecology. Its prevalence is higher in developed countries where the prevalence of obesity is also higher[1]. The most recent data indicate that in 2022, there will be 420,242 new cases of endometrial cancer globally, representing 2.1% of the total number of new malignant tumours worldwide and ranking 15th[2]. Additionally, there will be 97,704 new deaths, accounting for 1% of the total number of deaths from malignant tumours globally and ranking 19th[2]. The incidence of endometrial cancer continues to increase on an annual basis, largely due to the prevalence of a high-fat diet and sedentary lifestyle in recent years. The treatment of endometrial cancer is based on a combination of surgical treatment, supplemented by radiotherapy and chemotherapy[3]. Studies have demonstrated that the five-year survival rate for stage I and II endometrial cancer can reach 95%, whereas the five-year survival rate for stage III and IV decreases to 60%[3-4]. Sheman EN[5] and colleagues have developed a Relative Risk Index (RR) of endometrial cancer for patients with a body mass index (BMI) greater than 32, which is equal to 3.5. This indicates that patients are at a significantly increased risk of endometrial cancer. Consequently, endometrial cancer represents a significant health concern. Early screening has the dual benefit of improving survival outcomes and optimising survival rates. This is achieved by diagnosing and treating endometrial cancer at a curable stage. Furthermore, early screening reduces the burden and cost of treatment for patients.

Transvaginal ultrasonography (TVS) is a commonly employed diagnostic tool in the initial detection and screening of endometrial cancer[6]. It should be noted that transvaginal ultrasonography (TVS) has the potential to produce a significant number of false-positive results. A study by Smith-Bindman et al. revealed a 39% false-positive rate for transvaginal ultrasound measurements of endometrial thickness greater than 5 mm[7]. The occurrence of false-positive results has the potential to subject patients to a number of burdensome consequences. These include the necessity for invasive diagnostic procedures, such as curettage, which are costly and may cause distress. Additionally, patients may experience psychological distress, financial burden due to the costs of testing and treatment, and physical injury. It is therefore imperative to identify a convenient, cost-effective and non-invasive diagnostic method to reduce the rate of false-positive TVS.

Conversely, transvaginal ultrasound (TVS) has the potential to yield a considerable number of false-negative results. In a study conducted by Smith-Bindman and colleagues, which included 5,892 subjects, it was demonstrated that the false-negative rate of TVS for endometrial cancer surveillance is contingent upon the endometrial thickness criterion. When endometrial thickness was utilized as a criterion of 5 mm, the false-negative rate was approximately 5%. Additionally, the false-negative rate of TVS is influenced by age and the utilisation of tamoxifen medication, which results in an imprecise diagnosis of endometrial cancer[7]. In the event of a negative TVS result, patients are typically observed and followed up on a regular basis. A false negative TVS result indicates that a malignant tumour has been misdiagnosed as a benign condition, which may result in a delay in treatment, progression of the malignancy, and potentially even the development of an advanced stage. Consequently, patients will be forced to endure the detrimental consequences of an unfavourable prognosis, elevated treatment costs, diminished quality of life and diminished survival. It is therefore imperative to identify a convenient, cost-effective and non-invasive diagnostic method to reduce the false-negative rate of TVS.

The detection of novel tumour markers in serum has led to the identification of microRNAs as potential biomarkers for cancer. Shenzhen KeRuiDa Health Technology Co has developed an in vitro diagnostic test, the YiDiXie™ all-cancer test (hereinafter referred to as 'the YiDiXie™ test'),

which is capable of detecting a variety of cancer types with a minimal amount of biological material, specifically 200 microlitres of whole blood or 100 microlitres of serum[8]. The YiDiXie™ test comprises three distinct assays: YiDiXie™-HS, YiDiXie™-SS and YiDiXie™ -D.

The objective of this study is to assess the diagnostic efficacy of the YiDiXie™-SS and the YiDiXie™-HS tests in the context of endometrial cancer.

PATIENTS AND METHODS

Study design

This work constitutes a sub-study, entitled 'Evaluating the value of the YiDiXie™ test as an adjunctive diagnostic in a variety of tumours', of the SZ-PILOT study (ChiCTR2200066840).

The SZ-PILOT study (ChiCTR2200066840) is a single-centre, prospective, observational study design. Subjects who had provided written, informed consent for the donation of residual samples at the time of admission or physical examination were enrolled in the study, and 0.5 ml of their residual serum samples were collected for the purposes of this study.

The study was conducted in a blinded manner. The laboratory personnel who performed the YiDiXie™ test and the Coretta laboratory technicians who determined the results of the YiDiXie™ test were both blinded to the subjects' clinical information. The clinical experts who evaluated the clinical data of the subjects were also unaware of the results of the YiDiXie™ test.

The study was approved by the Ethics Committee of Peking University Shenzhen Hospital and was conducted in accordance with the International Conference on Harmonisation (ICH) Code of Practice for the Quality Management of Clinical Trials of Pharmaceuticals and the Declaration of Helsinki.

Participants

The two groups of subjects were enrolled separately, and all subjects who met the inclusion criteria were consecutively included.

The study initially included inpatients with a suspected solid or haematological malignancy who had provided general informed consent for the donation of remaining samples. Individuals with a postoperative pathological diagnosis of malignant tumour were categorised within the malignant group, while those with a postoperative pathological diagnosis of benign disease were included in the benign group. Those subjects with ambiguous pathological findings were excluded from the study. A number of samples from the malignant group and samples from healthy subjects in the benign group have been used in previous studies[8].

Subjects who failed the serum sample quality test prior to the YiDiXie™ test were excluded from the study. For further details regarding the inclusion and exclusion criteria, please refer to the previous article published by this research group[8].

Sample collection, processing

The serum samples utilized in this study were procured from surplus serum obtained from routine medical consultations, obviating the necessity for additional blood sampling. Approximately 0.5ml of serum was collected from the remaining serum of subjects in the Medical Laboratory Department and stored at -80°C for subsequent utilisation in the the YiDiXie™ test.

The YiDiXie test

The YiDiXie™ test is conducted using the YiDiXie™ all-cancer detection kit, an in vitro diagnostic kit for use in fluorescent quantitative PCR instruments developed and manufactured by Shenzhen KeRuiDa Health Technology Co[8]. The test is an in vitro diagnostic kit designed for use in

fluorescent quantitative PCR instruments. The test determines the presence of cancer in a subject's body by measuring the expression levels of dozens of miRNA biomarkers in the serum[8]. The test predefines appropriate thresholds for each miRNA biomarker, thereby ensuring that each miRNA marker is highly specific[8]. Furthermore, it integrates these independent assays in a concurrent testing format, which significantly increases sensitivity while maintaining specificity for broad-spectrum cancers[8].

The YiDiXie™ test is comprised of three distinct tests, each with unique characteristics. The YiDiXie™-HS, the YiDiXie™-SS and the YiDiXie™-D tests are characterised by high accuracy, precision and diagnostic capabilities, respectively[8]. The YiDiXie™-HS test has been developed with sensitivity and specificity as primary considerations[8]. The YiDiXie™-SS test has significantly expanded the number of miRNA tests, thereby achieving extremely high sensitivity for all malignancy types and all clinical stages[8]. The YiDiXie™-D test markedly elevates the diagnostic threshold of a singular miRNA examination, thereby attaining an exceptionally high sensitivity for all clinical stages of all malignant tumour types[8]. Furthermore, it achieves an exceptionally high specificity for the full range of malignant tumour types[8].

The YiDiXie™ test should be performed in accordance with the instructions provided in the YiDiXie™ Whole Cancer Test Kit. For further details on the procedure, please refer to the previous article in this series[8].

The raw test results are subjected to analysis by the laboratory technicians of Shenzhen KeRuiDa Health Technology Co., Ltd., who determine the results of the YiDiXie™ Test as either 'positive' or 'negative'[8].

Ultrasound diagnosis

The diagnostic findings of the ultrasound of the uterus are classified as either positive or negative. A positive diagnosis is indicated when the findings are indicative of a malignant tumour, or when the probability of a malignant tumour is higher than that of a benign tumour. In the event that the diagnosis is positive, more certain, or indicative of a benign tumour, or if the diagnosis is ambiguous, it will be classified as negative.

Extraction of clinical data

The data set comprised clinical, pathological, laboratory and imaging data extracted from the inpatient medical records or physical examination reports of the subjects. Clinical staging was conducted by trained clinicians in accordance with the AJCC staging manual (seventh or eighth edition)[9-10].

Statistical analyses

Descriptive statistics were employed to present the data pertaining to the demographic and baseline characteristics. For categorical variables, the number and percentage of subjects in each category were calculated. For continuous variables, the total number of subjects (n), mean, standard deviation (SD) or standard error (SE), median, first quartile (Q1), third quartile (Q3), minimum, and maximum values were calculated. The 95% confidence intervals (CIs) for the multiple indicators were calculated using the Wilson (score) method.

RESULTS

Participant disposition

A total of 74 study subjects were ultimately included in this investigation, comprising 58 cases belonging to the malignant group and 16 cases belonging to the benign group. The demographic and clinical characteristics of the 74 study subjects are presented in Table 1 for reference.

The two groups of study subjects were found to be comparable in terms of demographic and clinical characteristics (see Table 1). The mean age of the subjects was 52.6 years (standard deviation 11.04).

Table 1. Participants' demographic and clinical manifestation						
	Cancer (n = 58)		Benign (n = 16)		Total (N = 74)	
Age, years						
Mean (SD)	54.4	(9.39)	46.1	(14.15)	52.6	(11.04)
Median (Q1,Q3)	54	(48, 60)	47	(33, 53)	53	(46, 60)
Min, max	33,	80	26,	71	26,	80
Age, group, n (%)						
< 50	21	(36.2)	10	(62.5)	31	(41.9)
⩾ 50	37	(63.8)	6	(37.5)	43	(58.1)
< 65	49	(84.5)	14	(87.5)	63	(85.1)
⩾ 65	9	(15.5)	2	(12.5)	11	(14.9)
Body mass index (kg/m2)						
n	35		11		46	
Mean (SD)	25.0	(3.98)	23.9	(3.69)	24.7	(3.90)
Median (Q1,Q3)	24.4	(22.5, 27.3)	23.4	(22.0, 25.6)	24.3	(22.1, 26.8)
Min, max	17.5	34.0	19.1	32.8	17.5	34.0
Body mass index category, n (%)						
Underweight	4	(6.9)	0	(0)	4	(5.4)
Benign	9	(15.5)	6	(37.5)	15	(20.3)
Overweight	14	(24.1)	4	(25.0)	18	(24.3)
Obese	8	(13.8)	1	(6.3)	9	(12.1)
Missing	23	(39.7)	5	(31.2)	28	(37.8)
AJCC clinical stage						
Stage I	45	(77.6)			45	(77.6)
Stage II	5	(8.6)			5	(8.6)
Stage III	6	(10.3)			6	(10.3)
Stage IV	2	(3.4)			2	(3.4)
Q1,Q3, first quartile, third quartile; SD, standard deviation.						

Diagnostic performance of YiDiXie™-SS

As shown in Table 2, the sensitivity of YiDiXie™-SS was 98.3% (95% CI: 90.9% - 99.9%; 57/58) and its specificity was 62.5% (95% CI: 38.6% - 81.5%; 10/16) 61.2% (49.2% - 72.0%; 41/67).

Table 2. The performance of YiDiXie™-SS			
	Cancer	Benign	Total
	58	16	74
Positive	57	6	63
Negative	1	10	11
SEN = 57/58 = 98.3% (90.9% - 99.9%)		SPE = 10/16 = 62.5% (38.6% - 81.5%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic performance of YiDiXie™-HS

As shown in Table 3, the sensitivity of YiDiXie™-HS was 82.8% (95% CI: 71.1% - 90.4%; 48/58) and its specificity was 81.3% (95% CI: 57.0% - 93.4%: 13/16).

Table 3. The performance of YiDiXie™-HS			
	Cancer	Benign	Total
	58	16	74
Positive	48	3	51
Negative	10	13	23
SEN = 48/58 = 82.8% (71.1% - 90.4%)		SPE = 13/16 = 81.3% (57.0% - 93.4%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic performance of ultrasound

As demonstrated in Table 4, the sensitivity of uterine ultrasound was 34.5% (95% CI: 23.6% - 47.3%; 20/58), while its specificity was 75.0 (95% CI: 50.5% - 89.8%; 12/16).

Table 4. The performance of ultrasound			
	Cancer	Benign	Total
	58	16	74
Positive	20	4	24
Negative	38	12	50
SEN = 20/58 = 34.5% (23.6% - 47.3%)		SPE = 12/16 = 75.0% (50.5% - 89.8%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic performance of YiDiXie™-SS in uterine ultrasound-positive patients

In order to address the issue of a high false-positive rate associated with uterine ultrasound, YiDiXie™-SS was employed in the context of patients with a positive uterine ultrasound result.

As illustrated in Table 5, the sensitivity of YiDiXie™-SS in uterine ultrasound-positive patients was 95.0% (95% CI: 76.4% - 99.7%; 19/20), while the specificity was 75.0% (95% CI: 30.1% - 98.7%; 3/4).

This indicates that the utilisation of YiDiXie™-SS has the potential to reduce the incidence of false-positive uterine ultrasound results by 75.0% (95% CI: 30.1% - 98.7%; 3/4) while simultaneously minimising the risk of malignant tumour leakage.

Table 5. The performance of YiDiXie™-SS in uterus ultrasound-positive patients			
	Cancer	Benign	Total
	20	4	24
Positive	19	1	20
Negative	1	3	4
SEN = 19/20 = 95.0% (76.4% - 99.7%)		SPE = 3/4 = 75.0% (30.1% - 98.7%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

The Diagnostic performance of YiDiXie™-HS in uterine ultrasound-negative patients

In order to address the challenge of the high false-negative rate of uterine ultrasound, the application of YiDiXie™-HS was conducted in patients who had undergone a negative uterine ultrasound.

As demonstrated in Table 6, the sensitivity of YiDiXie™-HS in patients with negative uterine ultrasound results was 81.6% (95% CI: 66.6% - 90.8%; 31/38), while the specificity was 83.3% (95% CI: 55.2% - 97.0%; 10/12).

This indicates a reduction of 81.6% (95% CI: 66.6% - 90.8%; 31/38) in the incidence of false-negative uterine ultrasound results with the implementation of YiDiXie™-HS.

Table 6. The performance of YiDiXie™-HS in uterus ultrasound-negative patients			
	Cancer	Benign	Total
	38	12	50
Positive	31	2	33
Negative	7	10	17
SEN = 31/38 = 81.6% (66.6% - 90.8%)		SPE = 10/12 = 83.3% (55.2% - 97.0%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

DISCUSSION

Clinical significance of YiDiXie™-SS in uterine ultrasound-positive patients

In patients with a positive uterine ultrasound, the utilisation of supplementary diagnostic techniques is crucial for optimising sensitivity and specificity. In general, a positive result on a uterine ultrasound scan is followed by diagnostic curettage rather than radical surgery. Consequently, a false-positive uterine ultrasound does not result in significant adverse outcomes such as major surgical trauma, organ removal, or loss of function. Therefore, the probability of an undiagnosed malignant tumour is considerably higher than that of a misdiagnosed benign tumour in patients with a positive uterine ultrasound. Accordingly, YiDiXie™-SS was selected to diminish the false-positive rate of uterine ultrasound, exhibiting an exceptionally high sensitivity but a somewhat diminished specificity.

As demonstrated in Table 5, the YiDiXie™-SS in patients with a positive uterine ultrasound was 95.0% (95% CI: 76. The sensitivity was 95.0% (95% CI: 76.0% - 99.7%; 19/20), while the specificity was 75.0% (95% CI: 30.1% - 98.7%; 3/4). These results indicate that, while maintaining a sensitivity of nearly 100%, YiDiXie™-SS reduced the number of false positives identified by uterine ultrasound by 75.0% (95% CI: 30.1% - 98.7%; 3/4).

The results demonstrate that YiDiXie ™ -SS markedly diminishes the likelihood of erroneous diagnostic curettage in patients with benign endometrial disease, while concurrently exhibiting minimal propensity for unidentified malignancies. Consequently, YiDiXie™-SS is an effective solution that addresses a significant clinical need and has important clinical significance and wide application prospects.

Clinical implications of YiDiXie™-HS in uterine ultrasound-negative patients

In patients with a negative uterine ultrasound, the sensitivity and specificity of subsequent diagnostic techniques are of significant importance. A higher false-negative rate results in an increased number of malignant tumours being under-diagnosed. This can lead to delays in treatment. A higher false-positive rate indicates an increased likelihood of misdiagnosis of benign diseases Accordingly, the highly sensitive and specific YiDiXie™-HS was selected as a means of reducing the false negative rate of uterine ultrasound.

As demonstrated in Table 6, the sensitivity of YiDiXie ™ -HS in patients with negative uterine ultrasound was 81.6% (95% CI: 66.6% - 90.8%; 31/38), while the specificity was 83.3% (95% CI: 55.2% - 97.0%; 10/12). These findings demonstrate that YiDiXie™-HS has the potential to reduce false-negative uterine ultrasound results by 81.6% (95% CI: 66.6% - 90.8%; 31/38).

The aforementioned results indicate that YiDiXie™-HS markedly diminishes the likelihood of false-negative uterine ultrasound results in cases where malignancies are overlooked. It can therefore be concluded that YiDiXie ™ -HS meets the clinical requirements and has significant clinical importance and potential for wide application.

The YiDiXie™ test can address the two challenges of endometrial cancer

Firstly, the use of YiDiXie ™ -SS has the potential to significantly reduce the administrative workload of obstetricians and gynaecologists, thereby facilitating the timely diagnosis and prompt treatment of malignancy cases that would otherwise be delayed. In the event of a positive result on the uterine ultrasound, a diagnostic curettage is typically performed on the patient. The timely completion of these diagnostic scrapings is contingent upon the number of obstetricians and gynaecologists available. In numerous regions across the globe, appointments are scheduled months or even years in advance. This inevitably results in delays to the treatment of malignant

cases, with the consequence that patients with positive ultrasound results awaiting diagnostic curettage may show evidence of disease progression or even distant metastases. As demonstrated by the results, YiDiXie™-SS was observed to reduce the rate of false-positive uterine ultrasound by 75.0% (95% CI: 30.1% - 98.7%; 3/4), with essentially no increase in missed malignancies. Consequently, YiDiXie™-SS has the potential to markedly reduce the superfluous workload of obstetricians and gynaecologists, thereby facilitating the prompt diagnosis and treatment of endometrial cancer and other conditions that would otherwise be delayed.

Secondly, YiDiXie™-HS has the potential to significantly reduce the risk of underdiagnosis of endometrial cancer. In the event of a negative uterine ultrasound, the likelihood of endometrial cancer is typically discounted for the time being. The high rate of false-negative uterine ultrasound results consequently results in delayed treatment for a considerable number of endometrial cancer patients. As demonstrated in the results, YiDiXie™-HS was observed to reduce the false-negative rate of uterine ultrasound by 81.6% (95% CI: 66.6% - 90.8%; 31/38). Consequently, YiDiXie™-HS markedly diminishes the likelihood of false-negative uterine ultrasound results for undiagnosed malignancies, thereby expediting the diagnosis and treatment of patients with endometrial cancer who would otherwise experience delays in treatment.

Finally, the YiDiXie™ test enables the prompt identification of endometrial cancer. From the patient's perspective, the YiDiXi™ test requires only a minimal quantity of blood, enabling the diagnostic process to be completed without the need for invasive procedures and without the patient having to leave their home. A mere 20 microlitres of serum is necessary to complete a YiDiXie™ test, which is equivalent to approximately one drop of whole blood (one drop of whole blood is approximately 50 microlitres, yielding 20-25 microlitres of serum). In consideration of the pre-test sample quality assessment test and two or three repetitions, a volume of 0.2 ml of whole blood is sufficient for the YiDiXie™ Test. The 0.2 ml of finger blood can be collected at home by the average patient using a finger blood collection needle, obviating the need for venous blood collection by medical personnel. This allows the patient to complete the diagnostic process non-invasively without having to leave their home.

Conversely, the diagnostic capacity of the YiDiXie™ test is nearly unlimited. Figure 1 illustrates the fundamental operational sequence of the YiDiXie™ test, demonstrating that the test does not necessitate the involvement of a physician or specialized medical equipment, nor does it require the assistance of medical personnel for blood collection. Consequently, the YiDiXie™ Test is entirely independent of the number of medical personnel and medical institutions, and its testing capacity is effectively limitless. Consequently, the YiDiXie™ Test facilitates prompt diagnosis of endometrial cancer, obviating the need for patients to await appointments with trepidation.

In summary, the YiDiXie™ test is a valuable diagnostic tool for endometrial cancer. It is anticipated that the YiDiXie™ test will address the issues of a high false-positive rate and a high false-negative rate in endometrial cancer.

Figure 1. Basic flowchart of the YiDiXie™ test.

Limitations of the study

Firstly, the number of cases included in this study was relatively small, and it would be beneficial for future clinical studies to include larger sample sizes in order to facilitate further assessment.

Secondly, this study was a case-control study of malignant and benign tumours in inpatients, and further assessment would benefit from cohort studies in the natural population of endometrial cancer.

Finally, it should be noted that this study was conducted at a single centre, which may have introduced some degree of bias into the results. Further assessment would benefit from the inclusion of multicentre studies.

CONCLUSION

The YiDiXie™-SS has been demonstrated to markedly diminish the incidence of false-positive results in uterine ultrasound examinations, while concurrently demonstrating an insignificant propensity to delay the diagnosis of malignant conditions. The YiDiXie ™ -HS has been demonstrated to significantly reduce the rate of false-negative uterine ultrasound results. YiDiXie™ -SS and YiDiXie™-HS have significant diagnostic value in endometrial cancer, and are expected to solve the two problems of "high false positive rate of uterine ultrasound" and "high false negative rate of uterine ultrasound" in endometrial tumors.

FUNDING

This study was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).

REFERENCES

1. MICHAEL M. BRAUN D, ERIKA A. OVERBEEK-WAGER, DO, AND ROBERT J. GRUMBO, MD. Diagnosis and Management of Endometrial Cancer [J]. American family physician, 2016.

2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: A Cancer Journal for Clinicians, 2024, 74(3): 229-63.

3. Colombo N, Creutzberg C, Amant F, et al. ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up [J]. Radiotherapy and Oncology, 2015, 117(3): 559-81.

4. American Cancer Society: Key Statistics for Endometrial Cancer [J]. 2019.

5. Sherman M E, Sturgeon S, Brinton L A, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas [J]. Mod Pathol, 1997, 10(10): 963-8.

6. Capozzi V A, Merisio C, Rolla M, et al. Confounding factors of transvaginal ultrasound accuracy in endometrial cancer [J]. Journal of Obstetrics and Gynaecology, 2020, 41(5): 779-84.

7. Rebecca Smith-Bindman M K K, MD; Vickie A. Feldstein, MD; Leslee Subak, MD; Juergen Scheidler, MD; Mark Segal, PhD; Richard Brand, PhD; Deborah Grady, MD. Endovaginal Ultrasound to Exclude Endometrial Cancer and Other Endometrial Abnormalities [J]. JAMA, 1998.

8. Sun C, Lu C, Zhang Y, Wang L, Ge Z, Wen Z, Chen W, Li Y, Wu Y, Lin S et al.: Evaluation of the Mu lti-Cancer Early Detection (MCED) value of YiDiXie™-HS and YiDiXie™-SS. medRxiv: https://doi.org/10.11 01/2024.03.11.24303683, 2024.

9. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM [J]. Annals of Surgical Oncology. 17: 1471-1474, 2010.

10. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA: A Cancer Journal for Clinicians. 67: 93-99, 2017.